CN103012371A - 奥美拉唑钠结晶化合物、其制备方法及其药物组合物 - Google Patents
奥美拉唑钠结晶化合物、其制备方法及其药物组合物 Download PDFInfo
- Publication number
- CN103012371A CN103012371A CN2013100018922A CN201310001892A CN103012371A CN 103012371 A CN103012371 A CN 103012371A CN 2013100018922 A CN2013100018922 A CN 2013100018922A CN 201310001892 A CN201310001892 A CN 201310001892A CN 103012371 A CN103012371 A CN 103012371A
- Authority
- CN
- China
- Prior art keywords
- omeprazole sodium
- crystallization
- type crystallization
- preparation
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940063517 omeprazole sodium Drugs 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 title claims abstract 7
- 239000003814 drug Substances 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 title description 5
- 238000002347 injection Methods 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 6
- 238000004458 analytical method Methods 0.000 claims abstract description 4
- 238000002425 crystallisation Methods 0.000 claims description 55
- 230000008025 crystallization Effects 0.000 claims description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 7
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 238000000967 suction filtration Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 abstract description 5
- RRFCKCAQHRITRG-UHFFFAOYSA-N sodium;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-3-ide;hydrate Chemical compound O.[Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RRFCKCAQHRITRG-UHFFFAOYSA-N 0.000 description 28
- 239000000126 substance Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960000381 omeprazole Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001711 oxyntic cell Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- -1 sanitas Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310001892.2A CN103012371B (zh) | 2013-01-05 | 2013-01-05 | 奥美拉唑钠结晶化合物、其制备方法及其药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310001892.2A CN103012371B (zh) | 2013-01-05 | 2013-01-05 | 奥美拉唑钠结晶化合物、其制备方法及其药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103012371A true CN103012371A (zh) | 2013-04-03 |
CN103012371B CN103012371B (zh) | 2014-02-12 |
Family
ID=47961528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310001892.2A Active CN103012371B (zh) | 2013-01-05 | 2013-01-05 | 奥美拉唑钠结晶化合物、其制备方法及其药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103012371B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570687A (zh) * | 2013-11-15 | 2014-02-12 | 悦康药业集团有限公司 | 一种奥美拉唑钠晶体化合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1261362A (zh) * | 1997-06-27 | 2000-07-26 | 阿斯特拉公司 | 奥美拉唑钠盐 |
-
2013
- 2013-01-05 CN CN201310001892.2A patent/CN103012371B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1261362A (zh) * | 1997-06-27 | 2000-07-26 | 阿斯特拉公司 | 奥美拉唑钠盐 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570687A (zh) * | 2013-11-15 | 2014-02-12 | 悦康药业集团有限公司 | 一种奥美拉唑钠晶体化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN103012371B (zh) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210253521A1 (en) | Crystalline Eravacycline Bis-Hydrochloride | |
CN102659818A (zh) | 一种盐酸头孢替安晶体化合物及其制备方法及含该化合物的药物组合物 | |
CN111517980A (zh) | N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途 | |
CN103524532A (zh) | 一种头孢唑肟钠化合物晶型、制备方法及其药物制剂 | |
CN103012371B (zh) | 奥美拉唑钠结晶化合物、其制备方法及其药物组合物 | |
CN103494790B (zh) | 一种奥拉西坦胶囊及其制备方法 | |
AU2008210929A1 (en) | Novel crystal of piperacillin sodium | |
JP4566128B2 (ja) | イリノテカン塩酸塩の結晶多形の製造方法 | |
CN102796078A (zh) | 一种泮托拉唑化合物、制备方法及其药物制剂 | |
US9499565B2 (en) | Cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing same and uses thereof | |
CN102875532B (zh) | 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法 | |
CN103724359B (zh) | 一种无定形头孢替坦酸及由其制备头孢替坦二钠的方法和含有该头孢替坦二钠的药物组合物 | |
CN103145603A (zh) | 卡络磺钠化合物及其药物组合物 | |
CN103965115A (zh) | 一种5-氟胞嘧啶盐、其制备方法及应用 | |
CN110314143A (zh) | 注射用右旋奥拉西坦冻干制剂及其制备方法 | |
CN103536541B (zh) | 克拉霉素冻干粉针及其制备方法 | |
AU2009260075B2 (en) | Crystalline of eszopiclone, its composition, preparation and uses thereof | |
CN104814942A (zh) | 一种治疗消化系统疾病的药物泮托拉唑钠组合物胶囊 | |
CN102977107B (zh) | 一种培美曲塞二钠化合物及其组合物 | |
CN102584859B (zh) | 乳酸左旋尤利沙星晶体及其制备方法和用途 | |
CN102584858B (zh) | 乳酸左旋尤利沙星晶体及其制备方法和用途 | |
CN117486789A (zh) | 一种托拉塞米共晶盐及其制备方法和应用 | |
CN102424688B (zh) | 甲磺酸左旋尤利沙星晶体及其制备方法和用途 | |
CN102424689B (zh) | 甲磺酸左旋尤利沙星晶体及其制备方法和用途 | |
TW426527B (en) | Cinolone composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130403 Assignee: Hainan Chuntch Pharmaceutical Co., Ltd. Assignor: Ning Hui Contract record no.: 2014370000067 Denomination of invention: Omeprazole sodium crystalline compound, preparation method and medicine composition thereof Granted publication date: 20140212 License type: Common License Record date: 20140428 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130403 Assignee: Double Crane Pharmaceutical (Hainan) Co. Ltd. Assignor: Ning Hui Contract record no.: 2018370010001 Denomination of invention: Omeprazole sodium crystalline compound, preparation method and medicine composition thereof Granted publication date: 20140212 License type: Common License Record date: 20180207 Application publication date: 20130403 Assignee: Reyoung Pharmaceutical Co., Ltd. Assignor: Ning Hui Contract record no.: 2018370010002 Denomination of invention: Omeprazole sodium crystalline compound, preparation method and medicine composition thereof Granted publication date: 20140212 License type: Common License Record date: 20180207 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191014 Address after: 570311 No.2, SANHENG Road, Yaogu Industrial Park, Haikou national high tech Zone, Haikou City, Hainan Province Patentee after: Double Crane Pharmaceutical (Hainan) Co. Ltd. Address before: 266034 Shandong province Qingdao City, No. 129 Fuzhou Road, International Building Room 202 Patentee before: Ning Hui |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130403 Assignee: Reyoung Pharmaceutical Co., Ltd. Assignor: Double Crane Pharmaceutical (Hainan) Co. Ltd. Contract record no.: X2019980000634 Denomination of invention: Omeprazole sodium crystalline compound, preparation method and medicine composition thereof Granted publication date: 20140212 License type: Common License Record date: 20191119 |